BSX stent receives positive feedback
Boston Scientific Corp. debuted one-year results of its TAXUS stent, showing it to be superior to the Cypher stent in diabetic patients. The Natick-based firm conducted a study of 1,558 patients in 19 centers across the U.S.
The head-to-head study showed similarities between both patients using both the TAXUS stent and the Cypher stent, but in terms of target vessel revascularization (TVR), the study's primary endpoint, the TAXUS stent showed lower TVR in the complex diabetic patient population. TVR is needed when a patient undergoes a reoccurrence of symptons, and a lesion develops on a previously treated vessel.
In the complex diabetic patient population the TAXUS stent recorded a TVR rate of 2.8 percent as compared to the Cypher stent at 8.5 percent.
WBJ Web Partners
Most Recent
Most Recent
0 Comments